PPA
IOVA icon

Parametric Portfolio Associates’s Iovance Biotherapeutics IOVA Stock Holding History

Parametric Portfolio Associates’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$3.35M Buy
201,038
+21,372
+12% +$331K ﹤0.01% 2116
2021
Q4 		$3.43M Sell
179,666
-351,115
-66% -$7.73M ﹤0.01% 2109
2021
Q3 		$13.1M Buy
530,781
+263,782
+99% +$6.22M 0.01% 1184
2021
Q2 		$6.95M Buy
266,999
+77,965
+41% +$2.03M ﹤0.01% 1633
2021
Q1 		$5.99M Buy
189,034
+62,618
+50% +$2.6M ﹤0.01% 2040
2020
Q4 		$5.87M Buy
126,416
+15,451
+14% +$613K ﹤0.01% 1966
2020
Q3 		$3.65M Sell
110,965
-38,051
-26% -$1.17M ﹤0.01% 2110
2020
Q2 		$4.09M Buy
149,016
+37,013
+33% +$1.22M ﹤0.01% 2016
2020
Q1 		$3.35M Buy
112,003
+24,586
+28% +$652K ﹤0.01% 2030
2019
Q4 		$2.42M Buy
87,417
+860
+1% +$19.6K ﹤0.01% 2571
2019
Q3 		$1.57M Buy
86,557
+239
+0.3% +$5.29K ﹤0.01% 2790
2019
Q2 		$2.12M Buy
86,318
+64,405
+294% +$970K ﹤0.01% 2636
2019
Q1 		$208K Sell
21,913
-478
-2% -$4.64K ﹤0.01% 3709
2018
Q4 		$198K Buy
22,391
+4,054
+22% +$39.1K ﹤0.01% 3668
2018
Q3 		$206K Buy
18,337
+2,294
+14% +$32.6K ﹤0.01% 3749
2018
Q2 		$205K Sell
16,043
-86,595
-84% -$1.27M ﹤0.01% 3689
2018
Q1 		$1.74M Buy
102,638
+86,111
+521% +$1.3M ﹤0.01% 2708
2017
Q4 		$132K Buy
16,527
+49
+0.3% +$393 ﹤0.01% 3806
2017
Q3 		$128K Sell
16,478
-544
-3% -$3.44K ﹤0.01% 3932
2017
Q2 		$125K Buy
17,022
+1,131
+7% +$7.19K ﹤0.01% 3904
2017
Q1 		$118K Buy
15,891
+217
+1% +$1.59K ﹤0.01% 3680
2016
Q4 		$109K Sell
15,674
-23,175
-60% -$159K ﹤0.01% 3696
2016
Q3 		$320K Sell
38,849
-20
-0.1% -$169 ﹤0.01% 3385
2016
Q2 		$315K Buy
38,869
+24,092
+163% +$151K ﹤0.01% 3430
2016
Q1 		$75K Buy
+14,777
New +$80.9K ﹤0.01% 3898

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Parametric Portfolio Associates's IOVA Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Iovance Biotherapeutics (IOVA) stake by 12% in Q1 2022, buying an estimated $331K and bringing the position to 201,038 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2116.

Parametric Portfolio Associates first reported a position in IOVA in Q1 2016 and has held it in 25 quarters since. The position peaked at $13.1M in Q3 2021. 250 funds tracked by Wall St. Rank hold IOVA as of Q1 2022.

  • Parametric Portfolio Associates held 201,038 shares of Iovance Biotherapeutics worth $3.35M as of Q1 2022.
  • Parametric Portfolio Associates bought 21,372 Iovance Biotherapeutics shares in Q1 2022, an estimated $331K.
  • Iovance Biotherapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2116 holding.
  • Parametric Portfolio Associates first reported a position in Iovance Biotherapeutics in Q1 2016 and has held it in 25 quarters since.
  • Parametric Portfolio Associates's Iovance Biotherapeutics position peaked at $13.1M in Q3 2021.
  • 250 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.